Bioassays & Bioanalytical Method Development Session Spotlight: Development of a Novel Set of Release Assays for a Recombinant Influenza Vaccine

Most modern immunoanalysis was inspired by longstanding work in vaccine design - where, of course, an immunogenic result was the goal all along. How simple, effective, and accurate has it been to transition the methods meant to create immunogenic responses into now attempting to prevent them?

This year at the Bioassays and Bioanalytical Method Development Event, Vaxinnate will be on hand to take a closer look at this.  For more information on this session and the rest of the event, download the agenda.  As a reader of this blog, when you register to join us this October 1-3 in Berkley, California and mention code XP1768BLOG, you'll save 15% off the standard rate!

Featured Session: Development of a Novel Set of Release Assays for a Recombinant Influenza Vaccine

Speaker Scott Umlauf

Featured Speaker: Scott Umlauf, PhD, Director, Immunology and Analytical Testing, VAXINNATE
About the session: Creation of vaccines using recombinant protein technology can involve developing a novel set of release assays, at least some of which are biological in nature. VaxInnate’s technology utilizes a fusion of antigens with an innate immune stimulator.  Qualifying a cell-based assay for Toll-Like Receptor (TLR) activity has presented challenges, while replacing the Single Radial Immune Diffusion Assay (SRID) presents an opportunity to modernize influenza vaccine release assays.

• • Cell-based TLR assays should accurately predict in vivo responses
• • Curve discontinuity complicates mathematical analysis 
• • Replacement of in vivo potency assays with ELISA or SPR desirable

Share this article with your social network, just click below to share now!

Share |